CA3218510A1 - Small molecule modulators of glucocerebrosidase activity and uses thereof - Google Patents
Small molecule modulators of glucocerebrosidase activity and uses thereof Download PDFInfo
- Publication number
- CA3218510A1 CA3218510A1 CA3218510A CA3218510A CA3218510A1 CA 3218510 A1 CA3218510 A1 CA 3218510A1 CA 3218510 A CA3218510 A CA 3218510A CA 3218510 A CA3218510 A CA 3218510A CA 3218510 A1 CA3218510 A1 CA 3218510A1
- Authority
- CA
- Canada
- Prior art keywords
- substituted
- compound
- pharmaceutically acceptable
- certain embodiments
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163182734P | 2021-04-30 | 2021-04-30 | |
| US63/182,734 | 2021-04-30 | ||
| PCT/US2022/026676 WO2022232360A1 (en) | 2021-04-30 | 2022-04-28 | Small molecule modulators of glucocerebrosidase activity and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3218510A1 true CA3218510A1 (en) | 2022-11-03 |
Family
ID=83848814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3218510A Pending CA3218510A1 (en) | 2021-04-30 | 2022-04-28 | Small molecule modulators of glucocerebrosidase activity and uses thereof |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240246952A1 (https=) |
| EP (1) | EP4329880A4 (https=) |
| JP (1) | JP2024517789A (https=) |
| KR (1) | KR20240016286A (https=) |
| CN (1) | CN117751114A (https=) |
| AU (1) | AU2022267285A1 (https=) |
| BR (1) | BR112023022567A2 (https=) |
| CA (1) | CA3218510A1 (https=) |
| MX (1) | MX2023012853A (https=) |
| WO (1) | WO2022232360A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025237303A1 (zh) * | 2024-05-14 | 2025-11-20 | 先声药业有限公司 | β-葡萄糖脑苷脂酶变构调节剂、其药物组合物及用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0325956D0 (en) * | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| US7488721B2 (en) * | 2004-05-13 | 2009-02-10 | Mcmaster University | Real time methylumbelliferone-based assay |
| AU2009303441A1 (en) * | 2008-10-16 | 2010-04-22 | Schering Corporation | Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof |
| US8354403B2 (en) * | 2009-08-27 | 2013-01-15 | Merck Sharp & Dohme Corp. | Pyrrolidine derived beta 3 adrenergic receptor agonists |
| KR101880411B1 (ko) * | 2009-10-19 | 2018-07-19 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 중추신경계의 퇴행성 질환을 예방 및/또는 치료하는 신규 조성물 |
| HK1220325A1 (zh) * | 2013-03-15 | 2017-05-05 | Whitehead Institute For Biomedical Research | 苯并咪唑衍生物及其用途 |
| US9796680B2 (en) * | 2013-12-23 | 2017-10-24 | Alectos Therapeutics Inc. | Glucocerebrosidase modulators and uses thereof |
| CN108290855A (zh) * | 2015-07-01 | 2018-07-17 | 西北大学 | 被取代的喹唑啉化合物及其调节葡糖脑苷脂酶活性的用途 |
| WO2019027765A1 (en) * | 2017-08-02 | 2019-02-07 | Northwestern University | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS AND USES THEREOF |
| EP4039685A1 (en) * | 2021-02-08 | 2022-08-10 | Irbm S.P.A. | Azabicyclic shp2 inhibitors |
-
2022
- 2022-04-28 MX MX2023012853A patent/MX2023012853A/es unknown
- 2022-04-28 CA CA3218510A patent/CA3218510A1/en active Pending
- 2022-04-28 WO PCT/US2022/026676 patent/WO2022232360A1/en not_active Ceased
- 2022-04-28 US US18/288,933 patent/US20240246952A1/en active Pending
- 2022-04-28 EP EP22796703.1A patent/EP4329880A4/en active Pending
- 2022-04-28 JP JP2023567067A patent/JP2024517789A/ja active Pending
- 2022-04-28 AU AU2022267285A patent/AU2022267285A1/en active Pending
- 2022-04-28 CN CN202280046279.XA patent/CN117751114A/zh active Pending
- 2022-04-28 BR BR112023022567A patent/BR112023022567A2/pt unknown
- 2022-04-28 KR KR1020237041444A patent/KR20240016286A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022232360A1 (en) | 2022-11-03 |
| MX2023012853A (es) | 2024-01-12 |
| US20240246952A1 (en) | 2024-07-25 |
| EP4329880A1 (en) | 2024-03-06 |
| BR112023022567A2 (pt) | 2024-02-06 |
| AU2022267285A1 (en) | 2023-11-09 |
| KR20240016286A (ko) | 2024-02-06 |
| JP2024517789A (ja) | 2024-04-23 |
| EP4329880A4 (en) | 2025-03-05 |
| CN117751114A (zh) | 2024-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3652329B1 (en) | Compounds for tau protein degradation | |
| JP7427812B2 (ja) | 血漿カリクレインの阻害剤およびその使用 | |
| WO2018085247A1 (en) | Compounds for malt1 degradation | |
| WO2018165385A1 (en) | Inhibitors of malt1 and uses thereof | |
| CA3218259A1 (en) | Small molecule modulators of glucocerebrosidase activity and uses thereof | |
| EP4377306A1 (en) | Rock2 inhibitors and uses thereof | |
| CA3235270A1 (en) | Small molecule modulators of glucocerebrosidase activity and uses thereof | |
| CA3218510A1 (en) | Small molecule modulators of glucocerebrosidase activity and uses thereof | |
| JP2024539628A (ja) | グルコセレブロシダーゼ活性の小分子モジュレーターおよびその使用 | |
| CA3070717C (en) | Inhibitors of plasma kallikrein and uses thereof | |
| HK40123072A (en) | Inhibitors of plasma kallikrein and uses thereof | |
| HK40029252A (en) | Inhibitors of plasma kallikrein and uses thereof | |
| HK40029252B (en) | Inhibitors of plasma kallikrein and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250418 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250418 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260309 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260309 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260309 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260323 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260323 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260323 |